Chemoembolization Versus Radioembolization for Neuroendocrine Liver Metastases: A Meta-analysis Comparing Clinical Outcomes

Ngo, Lisa Y.; Elnahla, Ahmed; Attia, Abdallah S.; Hussein, Mostafa A.; Toraih, Eman A.; Kandil, Emad; Killackey, Mary

doi:10.1245/s10434-020-09469-4

Cited by 15 publications

(8 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…74,77 A large meta-analysis comparing outcomes between TACE and TARE in the treatment of neuroendocrine LM demonstrated that, despite similar tumor responses, there was an OS benefit was associated with TACE compared with TARE. 76 The RETNET trial is comparing the safety and efficacy of embolization techniques (bland, lipiodol, TACE, and DEB-TACE) for patients with neuroendocrine LM. After interim safety analysis, the DEB-TACE arm was permanently closed because of an observed high rate of serious adverse events.…”

Section: Impact Of Histology (Crc Vs Non-crc)mentioning

confidence: 99%

“…Although response rates for bland embolization is not associated with tumor histology, neuroendocrine tumors, especially carcinoids, appear to be associated with a greater response with TACE and TARE 74 . Although some studies demonstrate correlation between response rate and survival, 75,76 others do not 74,77 . A large meta‐analysis comparing outcomes between TACE and TARE in the treatment of neuroendocrine LM demonstrated that, despite similar tumor responses, there was an OS benefit was associated with TACE compared with TARE 76 .…”

Section: Summary Of Literature Reviewmentioning

confidence: 99%

“…Although some studies demonstrate correlation between response rate and survival, 75,76 others do not 74,77 . A large meta‐analysis comparing outcomes between TACE and TARE in the treatment of neuroendocrine LM demonstrated that, despite similar tumor responses, there was an OS benefit was associated with TACE compared with TARE 76 . The RETNET trial is comparing the safety and efficacy of embolization techniques (bland, lipiodol, TACE, and DEB‐TACE) for patients with neuroendocrine LM.…”

Section: Summary Of Literature Reviewmentioning

confidence: 99%

See 2 more Smart Citations

American Radium Society Appropriate Use Criteria for the use of liver‐directed therapies for nonsurgical management of liver metastases: Systematic review and guidelines

Hallemeier

Sharma

Anker

et al. 2023

Cancer

View full text Add to dashboard Cite

The liver is a common site of cancer metastases. Systemic therapy is widely accepted as the standard treatment for liver metastases (LM), although select patients with liver oligometastases may be candidates for potentially curative liver resection. Recent data support the role of nonsurgical local therapies such as ablation, external beam radiotherapy, embolization, and hepatic artery infusion therapy for management of LM. Additionally, for patients with advanced, symptomatic LM, local therapies may provide palliative benefit. The American Radium Society gastrointestinal expert panel, including members representing radiation oncology, interventional radiology, surgical oncology, and medical oncology, performed a systemic review and developed Appropriate Use Criteria for the use of nonsurgical local therapies for LM. Preferred Reporting Items for Systematic reviews and Meta‐Analyses methodology was used. These studies were used to inform the expert panel, which then rated the appropriateness of various treatments in seven representative clinical scenarios through a well‐established consensus methodology (modified Delphi). A summary of recommendations is outlined to guide practitioners on the use of nonsurgical local therapies for patients with LM.

show abstract

Section: Impact Of Histology (Crc Vs Non-crc)mentioning

confidence: 99%

Section: Summary Of Literature Reviewmentioning

confidence: 99%

Section: Summary Of Literature Reviewmentioning

confidence: 99%

See 1 more Smart Citation

American Radium Society Appropriate Use Criteria for the use of liver‐directed therapies for nonsurgical management of liver metastases: Systematic review and guidelines

Hallemeier

Sharma

Anker

et al. 2023

Cancer

View full text Add to dashboard Cite

show abstract

“…A recent meta-analysis revealed that patients treated with TACE had significantly better OS than those treated with TARE[ 67 ]. TARE proved to be more effective than TAE/TACE when Ki67 ≥ 3%, whereas Ki67 < 3% predicts a greater benefit with TACE[ 68 ].…”

Section: Advanced or Metastatic Diseasementioning

confidence: 99%

Therapeutic strategies for gastroenteropancreatic neuroendocrine neoplasms: State-of-the-art and future perspectives

Merola¹,

Michielan²,

Rozzanigo³

et al. 2022

WJGS

View full text Add to dashboard Cite

Although gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs) have always been considered rare tumors, their incidence has risen over the past few decades. They represent a highly heterogeneous group of neoplasms with several prognostic factors, including disease stage, proliferative index (Ki67), and tumor differentiation. Most of these neoplasms express somatostatin receptors on the cell surface, a feature that has important implications in terms of prognosis, diagnosis, and therapy. Although International Guidelines propose algorithms aimed at guiding therapeutic strategies, GEP-NEN patients are still very different from one another, and the need for personalized treatment continues to increase. Radical surgery is always the best option when feasible; however, up to 80% of cases are metastatic upon diagnosis. Regarding medical treatments, as GEP-NENs are characterized by relatively long overall survival, multiple therapy lines are adopted during the lifetime of these patients, but the optimum sequence to be followed has never been clearly defined. Furthermore, although new molecular markers aimed at predicting the response to therapy, as well as prognostic scores, are currently being studied, their application is still far from being part of daily clinical practice. As they represent a complex disease, with therapeutic protocols that are not completely standardized, GEP-NENs require a multidisciplinary approach. This review will provide an overview of the available therapeutic options for GEP-NENs and attempts to clarify the possible approaches for the management of these patients and to discuss future perspectives in this field.

show abstract

“…In this issue of Annals of Surgical Oncology, Ngo et al 4 report the largest to-date effort comparing chemoembolization (TACE) with radioembolization (TARE) for patients with unresectable neuroendocrine liver metastases. 4 This well-done article describes a meta-analysis that studied data from six retrospective studies on NELM. In all six studies, the data seem to favor TACE for survival benefit.…”

mentioning

confidence: 99%

TACE or TARE for Unresectable Neuroendocrine Liver Metastases: Can we Finally Start to Focus on Value?

Scoggins

2021

Ann Surg Oncol

View full text Add to dashboard Cite

Chemoembolization Versus Radioembolization for Neuroendocrine Liver Metastases: A Meta-analysis Comparing Clinical Outcomes

Cited by 15 publications

References 30 publications

American Radium Society Appropriate Use Criteria for the use of liver‐directed therapies for nonsurgical management of liver metastases: Systematic review and guidelines

American Radium Society Appropriate Use Criteria for the use of liver‐directed therapies for nonsurgical management of liver metastases: Systematic review and guidelines

Therapeutic strategies for gastroenteropancreatic neuroendocrine neoplasms: State-of-the-art and future perspectives

TACE or TARE for Unresectable Neuroendocrine Liver Metastases: Can we Finally Start to Focus on Value?

Contact Info

Product

Resources

About